Want to see EDSA full AI Analyst Report?
Top Page
Edesa Biotech
(NASDAQ:EDSA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▼(-49.39% Downside)
Action:Reiterated
Date:10/24/26
The score is weighed down primarily by weak financial performance (no revenue, significant ongoing losses, and sustained cash burn despite low debt). Technicals also pressure the score as the stock trades below key moving averages with negative MACD. Valuation provides limited offset because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Low Leverage
Effectively zero debt reduces solvency and interest-burden risk while preserving financial flexibility for clinical development. Although the company remains loss-making, its low leverage means fewer obligations compete with research spending and future financing needs.
Negative Factors
No Operating Revenue
Zero revenue means Edesa has not yet established an operating business capable of funding itself. The company therefore remains dependent on successful clinical development and eventual commercialization, leaving near-term financial performance disconnected from product demand or recurring customer income.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Effectively zero debt reduces solvency and interest-burden risk while preserving financial flexibility for clinical development. Although the company remains loss-making, its low leverage means fewer obligations compete with research spending and future financing needs.
Read all positive factors
Edesa Biotech (EDSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$34.99M
Dividend YieldN/A
Average Volume (3M)42.85K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS Growth-27.34%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.69
Shares Outstanding13,511,531
10 Day Avg. Volume49,614
30 Day Avg. Volume42,853
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap2.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-693.39
Enterprise Value/Ebitda-4.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.07
Revenue Forecast (FY)N/A
Edesa Biotech Business Overview & Revenue Model
Company Description
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline...
Edesa Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -102.84K | -119.27K | 0.00 | 0.00 | 0.00 | -118.79K |
| EBITDA | -14.28M | -7.07M | -6.13M | -8.46M | -17.47M | -13.22M |
| Net Income | -14.10M | -7.19M | -6.17M | -8.37M | -17.55M | -13.34M |
Balance Sheet | ||||||
| Total Assets | 12.72M | 13.53M | 3.81M | 8.89M | 11.58M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 10.33M | 10.79M | 1.04M | 5.36M | 7.09M | 7.84M |
| Total Debt | 0.00 | 0.00 | 19.87K | 94.49K | 18.98K | 99.32K |
| Total Liabilities | 3.91M | 1.08M | 1.83M | 1.84M | 2.18M | 1.53M |
| Stockholders Equity | 8.81M | 12.45M | 1.98M | 7.05M | 9.39M | 13.06M |
Cash Flow | ||||||
| Free Cash Flow | -8.95M | -7.32M | -4.89M | -6.64M | -12.28M | -13.67M |
| Operating Cash Flow | -8.95M | -7.32M | -4.89M | -6.64M | -12.28M | -13.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -5.66K | -6.15K |
| Financing Cash Flow | 7.04M | 17.03M | 592.03K | 4.83M | 11.63M | 14.17M |
Edesa Biotech Technical Analysis
Negative
4.94
Price Trends
4.01
Negative
5.12
Negative
5.63
Negative
Market Momentum
-0.42
Positive
29.71
Positive
26.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDSA, the sentiment is Negative. The current price of 4.94 is above the 20-day moving average (MA) of 3.23, above the 50-day MA of 4.01, and below the 200-day MA of 5.63, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 29.71 is Positive, neither overbought nor oversold. The STOCH value of 26.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EDSA.
Edesa Biotech Risk Analysis
Edesa Biotech disclosed 55 risk factors in its most recent earnings report. Edesa Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Edesa Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $48.10M | -4.91 | -50.77% | ― | 327.25% | 85.65% | |
49 Neutral | $53.22M | -4.36 | 83.45% | ― | ― | 15.65% | |
48 Neutral | $40.70M | -1.07 | 248.50% | ― | ― | 36.06% | |
46 Neutral | $37.78M | -1.25 | -26.78% | ― | ― | 65.39% | |
43 Neutral | $34.99M | -1.53 | -124.21% | ― | ― | -27.34% | |
40 Underperform | $12.86M | -0.21 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
EDSA
Edesa Biotech
2.59
0.43
19.91%
TIL
Instil Bio
5.57
-13.16
-70.26%
TCRX
TScan Therapeutics
0.19
-1.94
-91.13%
INKT
MiNK Therapeutics
10.43
-3.77
-26.55%
XLO
Xilio Therapeutics
7.31
-4.17
-36.32%
TVGN
Tevogen Bio Holdings
6.25
-23.99
-79.33%
Edesa Biotech Corporate Events
Business Operations and StrategyExecutive/Board Changes
Edesa Biotech Boosts Executive Compensation and Equity Alignment
Positive
Oct 23, 2026
On October 23, 2026, Edesa Biotech’s board approved substantial increases in the annual base salaries of Chief Executive Officer Dr. Pardeep Nijhawan, President Dr. Michael Brooks and Chief Financial Officer Peter Weiler, with the new pay le...
Business Operations and StrategyRegulatory Filings and Compliance
Edesa Biotech advances EB06 vitiligo Phase 2 trial
Positive
Oct 15, 2026
On October 15, 2026, Edesa Biotech reported that the U.S. Food and Drug Administration cleared its Investigational New Drug application for a Phase 2 clinical study of EB06 in vitiligo, allowing the company to expand patient recruitment from Canad...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.